Overview

Prostaglandin E1 in Outpatients With Intermittent Claudication

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
Investigate, under outpatient conditions, both the effect of 4 weeks of daily treatment with Prostaglandin E1 and that of 4 weeks of interval treatment (two infusions per week) on the pain-free walking distance in patients with Intermittent Claudication.
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Alprostadil
Pentoxifylline